Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Bezpečnost myeloablativních kondicionérů, Orca-T a alogenních T lymfocytů CD19/CD22-CAR (chimérický antigenní receptor) odvozených od dárce u dospělých s akutní lymfoblastickou leukémií B lymfocytů (ALL)

1. září 2026 aktualizováno: Melody Smith

Studie fáze I hodnotící bezpečnost myeloablativních podmínek, Orca-T a alogenních, od dárce odvozených CD19/CD22-CAR (chimérický antigenní receptor) T buněk u dospělých s B-buněčnou akutní lymfoblastickou leukémií (ALL)

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

22

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • California
      • Palo Alto, California, Spojené státy, 94305
        • Stanford Cancer Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Patient Inclusion Criteria:

  • Subjects in CR must have a history of chemotherapy refractory disease defined as progression or stable disease after one line of chemotherapy, or relapsed disease after achieving prior CR OR must have other high risk ALL features including: CRLF2 rearrangement, Ph-like phenotype, MLL/KMT2a rearrangement, or hypodiploid karyotype.

  • Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, PCR, FISH, or next generation sequencing) require verification of MRD in the peripheral blood or bone marrow on two occasions at least 2 weeks apart.

  • Subjects with active ALL (defined as >=5% bone marrow blasts, circulating blasts, or extramedullary disease) are eligible.

  • Age ≥ 18 and ≤ 65 years (i.e., from age 18 to < 66 years old) at the time of enrollment

  • Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2; or Karnofsky ≥ 60%

  • CD19 expression is required any time since diagnosis. CD19 expression may be detected by immunohistochemistry or by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. Patients receiving prior CD19 CAR T cell or blinatumomab are eligible if there is no documented history of CD19 negativity on the malignant cells.

  • Subjects must have an HLA matched related donor willing to undergo unstimulated apheresis for T cell collection for CAR T cell generation followed by GCSF mobilized apheresis for HSC/Treg graft.

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Subjects must have adequate organ function measured by:

    • Cardiac: Cardiac ejection fraction at rest ≥ 45%
    • Hepatic:
    • Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded and with approval of the study PI)
    • ALT/AST <= 3 times ULN
    • Renal: Calculated creatinine clearance ≥ 50 mL/min or serum creatinine < 2.0 mg/dL
    • Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
    • CNS: Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity.
  • Negative serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration

  • Subjects of childbearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for twelve (12) months after receiving the preparative conditioning regimen.

  • Must be able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.

Donor Inclusion Criteria

  • Age ≥ 18 and ≤ 75 years at time of enrollment

  • Karnofsky performance status of ≥ 70% defined by institutional standards

  • Willing to donate for two separate apheresis collections (T cells and PBSC)

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Negative serum or urine beta-HCG test in females of childbearing potential within 2 weeks of first apheresis

  • Seronegative for HIV-1 RNA PCR; HIV 1 and HIV 2 Ab (antibody); HTLV-1 and HTLV-2 Ab; PCR negative or sAg (surface antigen) negative for hepatitis B; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 40 days of donor apheresis procedures.

  • In the case that T pallidum antibody tests are positive, donors must:

    • Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history
    • Have completed effective antibiotic therapy to treat syphilis
    • Have a documented negative non-treponemal test (such as RPR) or in the case of a positive non-treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease

Patient Exclusion Criteria:

  • History of other malignancy unless disease free for at least 3 years. At the discretion of the Principal Investigator, subjects in remission for 1-2 years prior to enrollment may be deemed eligible after considering the nature of other malignancy, likelihood of recurrence for one year following therapy, and impact of prior treatment on risk of CD19/CD22-CAR T cells and Treg graft. Subjects in remission <1 year are not eligible. The following exceptions apply:

    • Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) is eligible.
    • Hormonal therapy in subjects in remission >1 year will be allowed.
  • Patients who have undergone a prior allogeneic or autologous stem cell transplant.

  • Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:

    • a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
    • the presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) >1000 by solid phase immunoassay
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.

  • Known history of infection with any of the following:

  • HIV

  • Hepatitis B (HBsAg positive) **

  • Hepatitis C virus (anti HCV positive) **

    ** A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.

  • Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.

  • Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab. For patients that have previously been exposed to a T cell-depleting agent, a 5-half-life washout of the agent must occur prior to planned Transplant Day 0.

  • Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • Pregnant or breast feeding

  • Patients with known autoimmune disease requiring the use of systemic immunosuppressive therapy within the last year

  • Presence of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement that in the judgment of the investigator may impair the ability to evaluate neurotoxicity.

  • Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment

Donor Exclusion Criteria

  • Evidence of active infection

  • Seropositive for HIV-1 or -2, HTLV-1 or -2

  • Positive PCR test results indicating acute or chronic HBV infection. Patients with isolated HBV core antibody positivity will not be excluded. Donors whose HBV infection status cannot be determined conclusively by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.

  • Potential for Zika virus infection as defined as any of the following:

    • Medical diagnosis of Zika virus infection in the past 6 months
    • Residence in, or travel to, an area with active Zika virus transmission within the past 6 months.
    • Unprotected sex within the past 6 months with a person who is known to have either of the risk factors listed above (donor exclusion criterion 5.a or 5.b)
  • Donors determined to be ineligible based on the results of Zika virus screening may be determined to be eligible if:

    o The donor has no signs or symptoms consistent with active Zika virus infection and

    o Either of the following is true: i. The donor is a first-degree or second-degree blood relative of the recipient ii. Urgent medical need, meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator.

  • Pregnant or breastfeeding female

  • Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Dose escalation

Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells

CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration

Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Patients Who Received Donor CD19/CD22-CAR T Cells
Časové okno: 42 days

Will be measured by the ability to manufacture donor CD19/CD22-CAR T cells that meet established release specifications

42 days
Assessment of the Donors Safety CD19/CD22-CAR T Cells Plus the Orca-T Graft
Časové okno: 42 days

Safety of the donor CD19/CD22-CAR T cells plus the Orca-T graft will be assessed by the incidence of engraftment without Grade III to IV acute GVHD

42 days

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cumulative Incidence of Disease Progression
Časové okno: 1 year

Measure by the cumulative incidence of relapse or progression of disease as well as non-relapse mortality (NRM) following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Frequency of Secondary Graft Failure
Časové okno: 1 year

Assessment of the rate of secondary graft failure following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Progression-free Survival
Časové okno: 1 year

progression-free survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Overall Survival
Časové okno: 1 year

overall survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Infectious Disease Complication
Časové okno: 1 year

Evaluate the incidence of greater than Grade 3 infectious disease complications

1 year

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Lori Muffly, MD, Stanford University

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

18. srpna 2022

Primární dokončení (Aktuální)

18. června 2025

Dokončení studie (Odhadovaný)

1. prosince 2045

Termíny zápisu do studia

První předloženo

17. srpna 2022

První předloženo, které splnilo kritéria kontroly kvality

17. srpna 2022

První zveřejněno (Aktuální)

19. srpna 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

28. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

1. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • IRB-64357
  • P01CA049605 (Grant/smlouva NIH USA)
  • NCI-2022-07232 (Jiný identifikátor: Clinical Trials Reporting Program Registration)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .